Fertility medicine

China Assisted Reproduction Market Insight Report, 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
General Health, Health, Family, Consumer, Articles, Fertility medicine, Medical specialties, Academic disciplines, Infertility, China, Reproduction, Assisted reproductive technology, Reproductive medicine

The "China Assisted Reproduction Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Assisted Reproduction Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • By the end of 2019, there were about 308 million women aged 21-49 in China, that is, about 38.5 million-46.2 million women of school age suffered from infertility.
  • To sum up, China's assisted reproductive industry has three characteristics: great market development potential, uneven distribution of assisted reproductive service resources, and strong dependence on imports of assisted reproductive medicines and instruments.
  • Great market development potential: 9.6 million infertile couples, with a market demand gap of 375.3 billion yuan to be met.

Generate Life Sciences to Provide DNA Ancestry Information in California Cryobank's Online Catalog

Retrieved on: 
Wednesday, August 4, 2021
Reproduction, Fertility medicine, Sperm donation, Semen, Branches of biology, Human reproduction, Giving, Cryobiology, Sperm bank, California Cryobank, Sperm, Donor Sibling Registry

LOS ANGELES, Aug. 4, 2021 /PRNewswire/ -- Generate Life Sciences today announced that California Cryobank, its industry-leading donor sperm bank, is now able to provide DNA-based donor ancestry information directly to prospective parents and donor-conceived children on Cryobank.com .

Key Points: 
  • LOS ANGELES, Aug. 4, 2021 /PRNewswire/ -- Generate Life Sciences today announced that California Cryobank, its industry-leading donor sperm bank, is now able to provide DNA-based donor ancestry information directly to prospective parents and donor-conceived children on Cryobank.com .
  • "Accessing direct-to-consumer ancestry services means sharing your most personal data with an online database, which may not appeal to many sperm donor-conceived families.
  • The DNA ancestry information for California Cryobank donors will be displayed as percentages on a world map divided into 26 distinct regions and ancestral groups.
  • For more information on Generate Life Sciences' DNA ancestry service, please visit cryobank.com/services/dna-ancestry .

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

Retrieved on: 
Wednesday, August 4, 2021
Reproduction, Human reproduction, Obstetrics, Fertility medicine, Cryobiology, Fertility, In vitro fertilisation, Human pregnancy, Embryo transfer, Pregnancy rate, Meta-analysis, Randomized controlled trial

The first paper, entitled Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomized clinical trials (Griesinger et al), was published in the Journal of Human Reproduction.

Key Points: 
  • The first paper, entitled Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomized clinical trials (Griesinger et al), was published in the Journal of Human Reproduction.
  • The study reports the results from a meta-analysis of three randomized, placebo-controlled trials showing that nolasiban increased the likelihood of live birth following IVF.
  • The analyses also showed that the effect size for nolasiban was similar for ongoing pregnancy rate and live birth rate.
  • Population pharmacokinetic analyses indicated that higher exposures of nolasiban were associated with a higher probability of pregnancy.

Feinstein Institutes receives $2.9M NIH grant for IVF genetic risk factors studies

Retrieved on: 
Monday, August 2, 2021
Health, Consumer, Genetics, Baby, Maternity, Research, Science, Branches of biology, Biology, Reproduction, Fertility medicine, National Human Genome Research Institute, In vitro fertilisation, Feinstein Institute for Medical Research, Natasha J. Caplen

To further study the accuracy and the ethics of PES, researchers at The Feinstein Institutes for Medical Research have been awarded a $2.9 million grant from the National Institutes of Health's (NIH) National Human Genome Research Institute (NHGRI).

Key Points: 
  • To further study the accuracy and the ethics of PES, researchers at The Feinstein Institutes for Medical Research have been awarded a $2.9 million grant from the National Institutes of Health's (NIH) National Human Genome Research Institute (NHGRI).
  • View the full release here: https://www.businesswire.com/news/home/20210802005445/en/
    Todd Lencz, PhD, professor in the Feinstein Institutes Institute of Behavioral Science and co-principal investigator on the new PES studies.
  • (Credit: The Feinstein Institutes for Medical Research)
    For decades, reproductive geneticists have been able to identify rare, serious genetic disorders like Down syndrome or cystic fibrosis prior to implantation of embryos in women undergoing IVF.
  • PES relies upon an examination of genetic differences scattered across the genome, each contributing a tiny amount of risk for a given disease; the total risk is measured by a polygenic risk score.

Global IVF Services Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Medical devices, Health, Consumer, Women, Parenting, Other Health, Fertility medicine, Reproduction, Human reproduction, Medical specialties, Cryobiology, Fertility, In vitro fertilisation, Fertility clinic, Genetics and IVF Institute, Pregnancy over age 50

The "IVF Services Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Cycle Type (Fresh IVF Cycles, Thawed IVF Cycles, and Donor Egg IVF Cycles); End User (Fertility Clinics, Hospitals, and Surgical Centers and Clinical Research Institutes), and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "IVF Services Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Cycle Type (Fresh IVF Cycles, Thawed IVF Cycles, and Donor Egg IVF Cycles); End User (Fertility Clinics, Hospitals, and Surgical Centers and Clinical Research Institutes), and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global IVF services market is expected to reach US$ 31,613.76 million by 2027 from US$ 13,496.29 million in 2019.
  • Based on cycle type, the IVF services market is segmented into fresh IVF cycles, thawed IVF cycles, and donor egg IVF cycles.
  • Based on end user, the IVF services market is segmented into hospitals, fertility clinics, and surgical centers and clinical research institutes.

Global Infertility Testing and Treatment Market (2021 to 2028) - Featuring Adorfem, Cook Medical and Cooper Surgical Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Genetics, Health, Medical devices, Fertility medicine, Medical specialties, Medicine, Clinical medicine, Infertility, Biopsy, Reproductive health

Additionally, technological advancements in time-lapse technology, coupled with advances in embryo biopsy and genetic screening, are generating new opportunities for the infertility testing and treatment market.

Key Points: 
  • Additionally, technological advancements in time-lapse technology, coupled with advances in embryo biopsy and genetic screening, are generating new opportunities for the infertility testing and treatment market.
  • The global infertility testing and treatment market covers North America, Asia-Pacific, Latin America, Europe, Middle East and Africa regions.
  • Globally, the Asia-Pacific is anticipated to witness the fastest growth rate in the infertility testing and treatment market over the forecast period.
  • Furthermore, the rise in healthcare awareness and availability of skilled professionals is likely to enhance the demand for these treatments, thereby augmenting the growth of the infertility testing and treatment market.

Global Vitrification Market Size, Share & Trends Analysis 2021-2027 by Specimen (Oocytes (Devices, Kits & Consumables), Embryo, Sperm), & End-use (IVF Clinics, Biobanks) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Medical devices, Health, Science, Research, Cryobiology, Reproduction, Human reproduction, Fertility medicine, Fertility, Human pregnancy, Obstetrics, Branches of biology, In vitro fertilisation, Vitrification, Freezing, Cryopreservation

The market is expected to expand at a CAGR of 17.7% from 2021 to 2027.

Key Points: 
  • The market is expected to expand at a CAGR of 17.7% from 2021 to 2027.
  • Several experiments and investigations have been conducted to prove the efficiency of vitrification over slow freezing, leading to its increased clinical implementation.
  • Currently, most IVF clinics are using this method to freeze the eggs/embryos and deliver a higher success rate to patients, thereby driving the market.
  • This has positively favored the high revenue share of this region in the market in 2020

U.S. In-Vitro Fertilization Market is Expected to Grow at a CAGR of 5.45% During the Period 2021-2026. - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Parenting, Pharmaceutical, Health, Consumer, Reproduction, Human reproduction, Human pregnancy, Fertility medicine, Fertility, Demographic economics, Cryobiology, In vitro fertilisation

The "U.S. In-Vitro Fertilization (IVF) Market - Industry Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. In-Vitro Fertilization (IVF) Market - Industry Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this U.S. In-vitro Fertilization Market Report
    The U.S. in-vitro fertilization market by revenue is expected to grow at a CAGR of 5.45% during the period 2021-2026.
  • The following factors are likely to contribute to the growth of the U.S. in-vitro fertilization market during the forecast period:
    The study considers the present scenario of the U.S. In-vitro fertilization market and its market dynamics for the period 2020-2026.
  • 4. Who are the key players in the US in-vitro fertilization market?

Female Infertility Treatment Drugs Market by Therapy, Route of Administration, Distribution Channel, and Region - Global Size, Share, Outlook, and Opportunity Analysis, 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Women, Consumer, Health, Parenting, Pharmaceutical, Fertility medicine, Organ systems, Medical specialties, Women\'s health, Women's health, Ferring Pharmaceuticals, Infertility, Female infertility, Polycystic ovary syndrome, Pharmaceutical industry in China, Evotec

The "Female Infertility Treatment Drugs Market, by Therapy, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Female Infertility Treatment Drugs Market, by Therapy, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Market players are focusing on various growth strategies such as agreements, partnerships, and collaborations to accelerate the development of drugs for infertility treatment, which is expected to boost growth of the global female infertility treatment drugs market over the forecast period.
  • For instance, in January 2020, Bayer AG announced the expansion of their partnership with Evotec SE, a biotechnology company focusing on women health, with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS), which is one of the causes of infertility in females.
  • Moreover, in January 2019, Ferring Pharmaceuticals, a biopharmaceutical company entered into an exclusive agreement with Sun Pharmaceutical Industries Ltd., an India-based multinational pharmaceutical company to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate injection which is used for treatment of female infertility.

Ovation Fertility Deploys Matcher Across Its Nationwide Network of IVF and Genetics Labs

Retrieved on: 
Thursday, July 22, 2021
Fertility medicine, Reproduction, Human reproduction, Articles, In vitro fertilisation, Cryopreservation, Embryo

Matcher is a barcode-based electronic witnessing, labeling, scheduling and traceability system, created for IVF centers and donor banks to help prevent errors caused by misidentification of patients and their gametes and embryos.

Key Points: 
  • Matcher is a barcode-based electronic witnessing, labeling, scheduling and traceability system, created for IVF centers and donor banks to help prevent errors caused by misidentification of patients and their gametes and embryos.
  • Matcher creates an electronic record of who, what, where and when at every step of the IVF, preimplantation genetic testing (PGT) and cryopreservation processes in the lab.
  • Ovation Fertility is a national network of reproductive endocrinologists and scientific thought leaders focused on reducing the cost of having a family through more efficient and effective fertility care.
  • Ovation also helps IVF labs across America improve their quality and performance with expert off-site lab direction and consultation.